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Abstract
Since its initiation in 1995, the African Program for Onchocerciasis Control (APOC) has had
a substantial impact on the prevalence and burden of onchocerciasis through annual iver-
mectin mass treatment. Ivermectin is a broad-spectrum anti-parasitic agent that also has an
impact on other co-endemic parasitic infections. In this study, we roughly assessed the
additional impact of APOC activities on the burden of the most important off-target infec-
tions: soil-transmitted helminthiases (STH; ascariasis, trichuriasis, hookworm, and strongy-
loidiasis), lymphatic filariasis (LF), and scabies. Based on a literature review, we formulated
assumptions about the impact of ivermectin treatment on the disease burden of these off-
target infections. Using data on the number of ivermectin treatments in APOC regions and
the latest estimates of the burden of disease, we then calculated the impact of APOC activi-
ties on off-target infections in terms of disability-adjusted life years (DALYs) averted. We
conservatively estimated that between 1995 and 2010, annual ivermectin mass treatment
has cumulatively averted about 500 thousand DALYs from co-endemic STH infections, LF,
and scabies. This impact comprised approximately an additional 5.5% relative to the total
burden averted from onchocerciasis (8.9 million DALYs) and indicates that the overall cost-
effectiveness of APOC is even higher than previously reported.
Author Summary
Onchocerciasis, or river blindness, is an infectious disease caused by the worm Onchocerca
volvulus, which is transmitted between humans through the bites of blackflies and causes
deforming skin disease, itch, and vision loss. The African Programme for Onchocerciasis
Control (APOC) aims to control morbidity due to onchocerciasis by implementing mass
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drug administration (MDA) with ivermectin in endemic areas, targeting the whole popu-
lation except for children under five and pregnant women. Aside from its effect on oncho-
cerciasis, ivermectin also affects other parasitic infections such as lymphatic filariasis,
intestinal worm infections, and scabies, which are all significantly co-endemic in areas
covered by APOC. In this paper, the researchers roughly estimate the health impact of
ivermectin MDA on off-target infections based on the number of dispensed treatments up
to 2010, published estimates of the disease burden of off-target infections, and the
expected effect of ivermectin treatment on the burden of these infections (based on litera-
ture review). This off-target health impact of APOC constitutes about 500 thousand years
worth of healthy years of life (an additional 5.5% on top of the impact of APOC on the
burden of onchocerciasis) and indicates that the cost-effectiveness of APOC is even higher
than previously estimated.
Introduction
The African Program for Onchocerciasis Control (APOC) is an international program aimed
at controlling the disease burden of human onchocerciasis (river blindness) in sub-Saharan
Africa (SSA), and elimination of infection where possible, using mass drug treatment (MDA)
[1,2]. Since its launch in 1995, APOC and partnering beneficiary countries have scaled up their
control activities geographically to at least cover all meso- and hyperendemic areas, averting
8.9 million disability-adjusted life years (DALYs) through 2010, and eventually aiming to treat
over 90 million people annually in 16 African countries by 2015, protecting a population at
risk of onchocerciasis of 118 million [3,4]. The drug used for mass treatment of onchocerciasis,
ivermectin, is distributed and administered in a single dose of 150–200 μg/kg of body weight
annually. Chronically ill people, pregnant (or lactating) women, and children under five are
excluded from treatment with ivermectin [1].
Ivermectin is known to be effective against various infectious diseases other than onchocer-
ciasis, the most important being soil-transmitted helminth (STH) infections, lymphatic filaria-
sis (LF), and epidermal parasitic skin diseases (EPSDs) such as scabies [5–11]. In APOC
countries, the prevalence of STH infections in school-age children ranges between 20% and
50% [12]. LF is endemic in all APOC countries with an estimated overall prevalence of 6–9%
[10], and local prevalences typically ranging between 0–40% [13]. Despite the lack of compre-
hensive epidemiological data, it is known that EPSDs are prevalent across SSA and that the
associated morbidity is significant in regions of high poverty [9,14,15]. Together, these infec-
tions are responsible for a considerable burden of disease [14,15]. Therefore, annual mass treat-
ment with ivermectin is expected to have an additional health impact by averting part of the
burden related to these off-target infections [8,16–19]. Although these additional beneficial
effects of ivermectin are being used to sensitise communities to participate in MDA, up till
now, the off-target health impact has not been quantified and its importance remains
unknown.
In this study, we quantified the health impact of APOC activities through 2010 on the bur-
den of STH (ascariasis, trichuriasis, hookworm, and strongyloidiasis), LF, and scabies. We
reviewed the literature to retrieve field studies examining the effect of ivermectin treatment on
off-target infections and formulated assumptions about the impact of ivermectin mass treat-
ment on the associated burden of disease. Next, we retrieved estimates of the disease burden of
candidate off-target diseases from the Global Burden of Disease (GBD) 2010 Study [14]. By
combining this information with data on the number of ivermectin treatments given through
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2010 (recorded by APOC), we roughly estimated the number of DALYs due to off-target infec-
tions averted by APOC.
Methods
Assumptions about effect of ivermectin on burden of off-target infections
We first performed a systematic PubMed search to determine efficacy of ivermectin mono-
treatment against off-target infection, defined as the ability to provide a clinically measurable
and preferably beneficial effect. We used the key term “ivermectin” in combination with any of
the following: “efficacy”, “mass treatment”, “morbidity control”. Searches were made without
time limitations. If available, meta-analysis studies evaluating the efficacy of ivermectin against
a specific disease were used. If meta-analysis studies were not available, clinical studies report-
ing the efficacy of treatment were selected if: (1) the treatment regime concerned a single dose
of about 150–200 μg/kg of body weight, and (2) the efficacy was evaluated up to one month for
STH infections and up to a year for filarial infections and EPSDs. We considered a month to be
the threshold duration of the immediate effect of ivermectin on STH infections. For LF and
EPSDs, longer periods were considered due to a lack of studies evaluating the efficacy of iver-
mectin as soon as one month after administration. Only studies reporting their results in terms
of the following criteria were considered: (1) percent of patients cured and/or percent egg
reduction for STH infections, (2) percent microfilaria (mf) reduction (microfilaricidal efficacy)
and/or the percent reduction in female fecundity (embryostatic efficacy) in LF, and (3) percent
of patients cured for EPSDs. For some EPSDs, clinical studies describing single cases were con-
sidered due to the rareness of their incidence. If repeated doses were given, it was noted.
Based on the results of the literature review, we formulated assumptions about the effect of
ivermectin mono-treatment on the burden of (untreated) off-target infections, in terms of
reduction in DALYs lost (Box 1). Assumptions were formulated while considering the follow-
ing factors: the direct effect of ivermectin treatment on infection levels in individuals, the clini-
cal manifestations of each disease, the short and long term effects of mass treatment on
incidence and prevalence of morbidity, and the patterns of post-treatment re-infection. The
effect of ivermectin was expressed as parameter βx (range 0–1), which represents the average
reduction in the burden of disease x in DALYs lost over a period of six years achieved thanks to
mass treatment with ivermectin. The six-year period was based on APOC data on population
coverage of ivermectin mass treatment, which suggest that most of the population in APOC
areas has been subject to at least six rounds of mass treatment between 1995 and 2010 [3]. For
infections such as STH and scabies, in which morbidity is highly correlated with intensity of
infection (parasite load), and treatment only influences transmission to a small extent, we
assumed that the impact of treatment is the same each year. For LF, repeated mass treatment
rounds are expected to have an increasingly higher impact on the disease burden, through the
effects of mass treatment on transmission and prevention of further exposure to infection that
would lead to chronic disability (e.g. lymphedema). We assumed that for LF, parameter βx rep-
resents the average health impact in all areas subject to varying periods of ivermectin mass
treatment.
Data sources for estimates of disease burden
From the GBD 2010 study [14], we derived country-specific estimates of the burden per capita
(DALYs lost per 100,000 persons) for ascariasis, trichuriasis, hookworm, LF, and EPSDs (sca-
bies only) in 1995, 2000, 2005, and 2010 (extracted from the online GBD data visualization tool
[20]). For the years in between, we assumed that the disease burden of these off-target infec-
tions followed a trend consistent with exponential interpolation of the available estimates. For
APOC 1995-2010: Impact on Off-Target Infectious Diseases
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Box 1. Reasoning and Assumptions Regarding the Effectiveness of
an Average Round of Mass Treatment (Parameter βx)
Ascariasis
A single dose of ivermectin is highly efficacious against Ascaris lumbricoides, reducing
fecal egg counts by 94–100% [28,29], and clearing infection in 78–100% [28–32]. The
clinical manifestations of ascariasis include: malnutrition, intestinal obstruction, growth
and cognitive delays [15,33]. They are associated with high intensity of infection (worm
burden) [34]. The immediate post-treatment health benefits include: weight/height gain,
increased fitness and physical activity [7,35]. The long-term health benefits of treatment
include: prevention of intestinal obstruction, increased school attendance, learning abili-
ties, and cognitive testing [7,18,35,36]. Field studies show that post-treatment reinfection
does not bring the worm burden or prevalence back to pre-treatment levels in treated
communities [19,37,38]. Based on this information, we assume that an average round of
mass treatment with ivermectin reduces the burden of ascariasis by 50% (βasc = 0.5).
Trichuriasis
A single dose of ivermectin has medium to high efficacy against Trichuris trichiura,
reducing fecal egg counts by 86–93% [29,30], and clearing infection in 35–67%[29–31].
The clinical manifestations of trichuriasis include: inflammatory bowel disease, growth
and cognitive delays [15,33], which are associated with high intensity of infection (worm
burden). The immediate post-treatment health benefits include: weight/height gain,
increased fitness and physical activity [7,35]. The long-term health benefits of treatment
include: prevention of inflammatory bowel disease, increased school attendance, learning
abilities, and cognitive testing [7,18,35,36]. Field studies show that post-treatment rein-
fection does not bring the worm burden or prevalence back to pre-treatment levels in
treated communities with high initial prevalence [19,36,37]. Based on this information,
we assume that an average round of mass treatment with ivermectin reduces the burden
of trichuriasis by 50% (βtrich = 0.5).
Hookworm infections
A single dose of ivermectin has low efficacy against Ancylostoma duodenale and Necator
americanus, reducing fecal egg counts by 52–80% [29,31], and clearing infection in 12–
33% [29,31,39]. The clinical manifestations of hookworm include: iron-deficiency ane-
mia, malnutrition, growth and cognitive delays, and poor pregnancy outcomes [15,33].
They are associated with high intensity of infection (worm burden). A round of mass
treatment has a small impact on the worm burden due to the low efficacy of the drug
[37]. The immediate post-treatment health benefits include: weight/height gain,
increased fitness [7,35]. The long-term health benefits of treatment include: prevention
of anemia, malnutrition, growth and cognitive delays. Field studies show that post-treat-
ment reinfection brings the prevalence back to pre-treatment values [19,36]. Based on
this information, we assume that an average round of mass treatment with ivermectin
reduces the burden of hookworm infections by 20% (βhook = 0.2).
APOC 1995-2010: Impact on Off-Target Infectious Diseases
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Strongyloidiasis
A single dose of ivermectin is highly efficacious against Strongyloides stercoralis, reducing
fecal larval counts by 94–100% [29,30], and clearing infection in 83–100% [16,30,40–42].
Ivermectin is considered to be the drug of choice for treating strongyloidiasis [42–46]. A
round of mass treatment rapidly lowers the worm burden the population [30,37,41,43].
The clinical manifestations of strongyloidiasis include: abdominal pain and discomfort,
diarrhea, weight loss, pruritus, and the potentially deadly dissemination (hyperinfection)
[45]. The immediate post-treatment health benefits include: prevention of abdominal
pain and discomfort, prevention of diarrhea, weight gain [45,46]. The long-term health
benefits of treatment include: prevention of potentially fatal dissemination of infection
[46]. Although S. stercoralis can persist in an untreated individual for years due to auto-
infection [47], once eradicated during treatment, an individual can only be re-infected
from the environment. Since no follow up studies were found in the literature for S. ster-
coralis reinfection, we assume that the environmental reinfection rate would be similar to
that of other STH infections. Based on this information, we assume that an average
round of mass treatment with ivermectin reduces the morbidity due to strongyloidiasis
by 50% (βstrong = 0.5).
Lymphatic filariasis (LF)
A single dose of ivermectin has high microfilaricidal (100%) and intermediate embryo-
static (35%) efficacy against LF [48]. Microfilariae start to reappear at three months post
treatment and reaches approximately 11% of pre-treatment values at twelve months
[49]. The clinical manifestations of LF include: adenolymphangitis, lymphedema, and
hydrocele. Existing morbidity is not cured or improved by clearing the microfilaria or
even the complete and persistent clearance of infection. Yet, through their impact on
transmission, repeated rounds of ivermectin mass treatment help to prevent the onset of
new cases and possibly the progression of early clinical manifestations [50]. Annual iver-
mectin mass treatment does not interrupt the transmission of LF [51]. However, given
population turnover and a reduced incidence (and possibly progression) of clinical mani-
festations, mass treatment indirectly decreases the prevalence of clinical symptoms of LF
over time. Based on this information, we assume that an average round of mass treat-
ment with ivermectin reduces the burden due to LF by 10% (βLF = 0.1).
Epidermal parasitic skin diseases (EPSDs)
A single dose of ivermectin is highly efficacious against EPSDs [6], causing an immediate
lowering of the intensity of infestation. One dose of ivermectin suppresses scabies infec-
tion for up to three months [52], and even clears infestation in 70–100% [53–55]. A
round of mass treatment lowers the intensity of infestation rapidly [56,57]. The clinical
manifestations of EPSDs include: pruritus (itching), and secondary streptococcal infec-
tions [9]. The immediate post-treatment health benefits include: prevention of secondary
infections, decreased physical and mental discomfort of severe pruritus, increased libido
[18,58,59]. The long-term health benefits of treatment include: prevention of streptococ-
cal pyoderma which in turn predisposes to rheumatic fever, acute glomerulonephritis
and their respective long-term sequelae: rheumatic heart disease and chronic renal insuf-
ficiency [9,60–63]. Based on this information, we assume that an average round of mass
treatment with ivermectin reduces the morbidity due to EPSDs by 50% (βoncho = 0.5)
APOC 1995-2010: Impact on Off-Target Infectious Diseases
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some countries covered by APOC, the GBD 2010 study reports a decline in the burden of off-
target diseases between 1995 and 2010. In the current study, we assume that this decline is not
due to APOC or other control activities, at worst leading to an underestimation of the health
impact of ivermectin mass treatment on off-target diseases (i.e. because the counterfactual bur-
den without these activities would be even higher than reported by GBD 2010).
Though the group of EPSDs consists of several infections such as scabies, tungiasis (sand
fleas), pediculosis (lice), and several other infections [9], for the purpose of this study, we only
considered scabies, as burden estimates have been made only for this particular infection so
far. Further, the GBD 2010 study does not provide estimates for the burden of strongyloidiasis,
an STH, even though its prevalence in SSA is probably considerable (although of unknown
size). We assumed that the burden due to strongyloidiasis amounts to 1/5 of the total burden
caused by the three major STH infections (ascariasis, trichuriasis, and hookworm). This
assumption was based on the estimate that the prevalence of the three major STH infections in
SSA ranges between 20–50% [12], and a large cross-sectional study in rural Ghana which
reported a prevalence of strongyloidiasis of 11.6% [21]. These figures suggest that the preva-
lence and presumably the burden of strongyloidiasis may be up to five times lower than the
prevalence and burden of the other three more common STH infections. Given the uncertainty
regarding the assumption, we varied it in the sensitivity analysis (details below).
Calculation of disease burden averted
We calculated the disease burden averted,Maiyx (in DALYs), for each selected off-target infec-
tion x and summed it over the sixteen countries in which APOC has been active between 1995
and 2010 using the following formula, where i represents a specific APOC country and y repre-
sents the year of mass treatment:
Max ¼
X16
i¼1
X2010
y¼1995
Maiyx ¼
X16
i¼1
X2010
y¼1995
bxTiyhix
1 pMcx  pMwx
1 pc pw Miyx
In this formula,Mixy reflects the annual burden per capita due to infection x (as reported by
the GBD 2010 study). This figure was adjusted to represent the burden per capita in population
eligible for mass treatment with ivermectin in APOC areas by adjusting for over- or underrep-
resentation of the disease burden in children under five and pregnant or lactating women who
are not eligible for ivermectin (1pMcxpMwx
1pcpw is the fraction
proportion of burden in ivermectineligible population
proportion of population eligible for ivermectin
,
where pMcx + pMwx is the proportion of the disease burden in children under ﬁve, and pc + pw
is the proportion of children under ﬁve and pregnant or lactating women in the population).
We further adjusted for clustering of disease burden in APOC regions compared to other coun-
try regions (hix). The adjusted burden per capita (hix
1pMcxpMwx
1pcpw Mixy) was then multiplied by
the number of treated individuals Tiy for any given year y (extracted from APOC records),
yielding the potential disease burden in treated people. Assumptions about the values of afore-
mentioned parameters can be found in Table 1, along with the associated literature references
[3,11,12,14,20,22–27]. The potential disease burden in treated people was multiplied with the
infection-speciﬁc ivermectin efﬁcacy βx, yielding the estimated averted disease burden related
to infection x in country i for year y. Results were then summed over years and countries,
resulting in a total estimated number of DALYs averted (Max), related to infection x.
Sensitivity analysis
A univariate sensitivity analysis was performed to assess how the main result (number of
DALYs averted related to off-target infections) changed when parameter βx was increased or
APOC 1995-2010: Impact on Off-Target Infectious Diseases
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decreased by 20%. The value of 20% was chosen because larger increases or decreases of the
effectiveness of ivermectin against off-target infections are highly unlikely to occur in field set-
tings. Likewise, the assigned value of hix was varied by ±20% for those countries where hix was
initially set to 1.5 (see Table 1). In addition, prevalence and burden of STH infections or EPSDs
were assumed to either be overrepresented in APOC regions for all or none of the countries
covered by APOC. The impact of the assumption regarding burden due to strongyloidiasis (1/5
of the total burden due to other STH infections) was examined by halving or doubling the
assumed proportion. Finally, we also performed a multivariate sensitivity analysis by simulta-
neously increasing or decreasing all assumed βx parameters by 20% as an extreme scenario.
Results
We assumed that each year, mass treatment would avert some fraction βx of the potential dis-
ease burden in treated communities. Based on literature, this fraction was assumed to be 0.5 for
ascariasis, trichuriasis, strongyloidiasis and EPSDs, 0.2 for hookworm infections, and 0.1 for LF
(Box 1).
We estimated that without APOC (counterfactual situation assuming that there is no mass
treatment with ivermectin by APOC), the potential disease burden of STH infections, lym-
phatic filariasis, and EPSD in individuals otherwise treated with ivermectin would amount to a
cumulative burden of 1.7 million DALYs between 1995 and 2010. Of these, 493 thousand
DALYs were averted by APOC through ivermectin mass treatment (Table 2). Most of the
DALYs averted by APOC were related to ascariasis (162 thousand) and scabies (116 thousand),
followed by LF (71 thousand), strongyloidiasis (67 thousand), and hookworm infection (61
thousand). Only a small part of the burden averted by APOC was related to trichuriasis (17
thousand). Nigeria contributed 53% of the total averted number of DALYs related to off-target
infections (260 thousand of 493 thousand), followed by the DRC (62 thousand or 13%) and
Cameroon (59 thousand or 12%).
Table 1. Description of parameters and their values.
Parameter Description Assumption or reference
Mixy Estimated burden of disease x per capita in country i
and year y (1995–2010)
Global Burden of Disease 2010 study [14,20].
Tiy Number of people treated in country i and year y
(1995–2010)
Coverage data from APOC records that were also used in a recent evaluation of
the health impact and cost of APOC activities [3,4].
hix Heterogeneity index for disease x in country i The spread of STH infections in APOC countries was assessed by visually
comparing REMO maps with maps published by the Global Atlas of Helminth
Infections [12,25]. h = 1.0, when STH infections are highly prevalent across the
whole country and 1.5 when certain areas of high prevalence of STH infections
overlap APOC regions. For LF, h = 1.0 for all countries. For all other infections,
h = 1.5 for CAR, Chad and Nigeria (as APOC covers about half of the
aforementioned countries, the hypothetical maximum value of h would be 2.0 for
those countries). For all other countries, we assumed h equal to 1.0.
pc + pw Proportion of children below ﬁve years of age and
pregnant women in the population
Assumed to be 0.2 for all countries, based on data from U.S. Census Bureau [27].
pMcx +
pMwx
Proportion of disease burden in pregnant women and
children under the age of ﬁve years
pMcx + pMwx = 0.2 if burden is evenly distributed over pregnant women, children
under ﬁve, and the rest of the population. For ascariasis and trichuriasis, pMcx +
pMwx = 0.1, since the burden in young children is considered substantial [23,24],
though highest in those eligible for treatment (5–14 years) [14]. For hookworm,
pMcx + pMwx = 0.3, since the burden in pregnant women is considered to be
substantial [22,26].
βx The average annual reduction in DALYs due to
infection x over six annual rounds of treatment
See Box 1.
doi:10.1371/journal.pntd.0004051.t001
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Fig 1 shows the results of the sensitivity analyses. Changing individual βx parameters by
20% resulted in estimates very similar to the main estimate. Obviously, increasing or decreasing
all βx parameters simultaneously by 20% resulted in ±20% deviations from the main estimate
of 493 thousand DALYs averted. Assumed no clustering of STH and EPSDs in APOC areas
(hix = 1.0) or clustering of all infections but LF in all countries (hix = 1.5) resulted in 16% lower
and 19% higher estimates of total DALYs averted, respectively.
Discussion
The impact of APOC on off-target NTDs has previously been discussed and considered to be
important, but difficult to quantify. We estimated that if APOC would not have been there,
STH infections, strongyloidiasis, and scabies would have caused a cumulative burden of 1.7
million DALYs lost between 1995 and 2010 in individuals who would otherwise have been
treated with ivermectin. We roughly estimated that of these 1.7 million DALYs, mass treatment
with ivermectin has averted 500 thousand DALYs. This means that apart from the impact of
APOC on the burden of onchocerciasis (8.9 million DALYs averted), there has been an addi-
tional 5.5% health impact through the effect of ivermectin mass treatment on off-target NTDs.
This indicates that the cost-effectiveness of APOC is even somewhat higher than previously
estimated.
The estimate of 500 thousand additionally averted DALYs was based on a simple approach
that included assumptions about the impact of mass treatment on the burden of selected off-
target infections endemic in APOC countries. Because we considered a period of six years for
estimating the effects of ivermectin mass treatment (i.e. the minimum duration of most APOC
programs), our approach may underestimate the averted burden in countries where ivermectin
Table 2. Burden of off-target infections averted by annual ivermectin mass treatment with ivermectin in Africa. Figures represent the cumulative bur-
den averted between 1995 and 2010 in areas covered by the African Programme for Onchocerciasis Control.
Burden averted by ivermectin mass treatment (DALYs x 1,000)a
Country Ascariasis Trichur-iasis Hook-worm Strongy-loidiasis Lymphatic ﬁlariasis Scabies Total (%)
Angola 0.2 0.1 0.2 0.1 0.2 0.2 0.9 (0.2%)
Burundi 0.4 0.1 1.3 0.7 0.8 1.2 4.6 (0.9%)
Cameroon 23.6 6.1 5.7 7.2 8.5 8.0 59.3 (12%)
Central African Republic 0.5 0.2 4.3 0.3 2.6 3.0 10.9 (2.2%)
Chad 0.1 0.0 3.2 2.1 1.8 8.6 15.8 (3.2%)
Congo 1.5 0.8 0.6 0.5 0.8 0.8 5.1 (1%)
Democratic Republic of Congo 18.1 5.5 11.9 1.6 11.0 14.0 62.0 (12.6%)
Equatorial Guinea 0.1 0.1 0.0 0.0 0.1 0.0 0.3 (0.1%)
Ethiopia 2.6 1.7 2.5 0.1 2.2 8.0 17.2 (3.5%)
Liberia 1.1 0.5 3.0 3.7 2.0 2.9 13.2 (2.7%)
Malawi 0.3 0.0 0.7 2.6 0.4 5.3 9.2 (1.9%)
Nigeria 112.0 1.2 20.5 45.3 31.8 49.1 259.9 (52.8%)
Sudan and South Sudanb 0.1 0.0 0.9 1.9 0.6 5.5 9.0 (1.8%)
Uganda 0.6 0.2 3.3 3.4 2.0 4.2 13.8 (2.8%)
United Republic of Tanzania 0.2 0.5 2.9 1.2 1.8 4.9 11.5 (2.3%)
Total 161.5 16.9 61.0 70.9 66.6 115.7 492.5 (100%)
a These ﬁgures are the product of the potential disease burden due to off-target infections in people treated with ivermectin and the assumed effect of
ivermectin treatment on the disease burden (see Box 1).
b Estimates for Sudan and South Sudan are merged, as information on the burden per capita was reported for the two together [14].
doi:10.1371/journal.pntd.0004051.t002
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mass treatments have taken place for over six years (i.e. where effects on transmission may be
larger). Also, we did not take into account the protective impact of ivermectin mass treatment
due to a reduced transmission to children under five years of age and pregnant women (who
receive no ivermectin). Gutman et al. show that the prevalence of some STH infections was sig-
nificantly lower in pre-school children living in treated communities compared to pre-school
children living in non-treated communities [19]. Further, we assumed that APOC interven-
tions have not been accounted for in the burden estimates for off-target NTDs provided by the
GBD 2010 study, meaning that at worst (if GBD 2010 does account for APOC), ivermectin
mass treatment has had a larger health impact than we estimate here. Also, ivermectin mass
treatment probably has an effect on the burden of relatively rare or minor infections that were
excluded from our analysis, such as enterobiasis, loiasis, streptocerciasis, serous cavity filariasis,
and EPSDs other than scabies. Furthermore, ivermectin mass treatment also has a–yet to be
quantified–effect on malaria transmission through the endectocidal effects of ivermectin on
Anopheles vectors [64]. On the other hand, we did not consider the burden of severe adverse
effects of ivermectin treatment related to loiasis [65,66], which is endemic in parts of the
APOC region [67]. Overall, if anything, our results underestimate the true impact of APOC
activities on off-target infections.
Our estimates of the impact of APOC on the burden of off-target diseases could be further
refined with more sophisticated approaches, such as mathematical modeling. For some of the
Fig 1. Sensitivity analysis for the impact of assumed parameter values on the total averted burden. For each parameter (y-axis), the figure between
brackets indicates the relative amount by which it was varied in the sensitivity analysis.
doi:10.1371/journal.pntd.0004051.g001
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off-target infections, mathematical models have already been developed, such as for transmis-
sion and morbidity due ascariasis and transmission of lymphatic filariasis [22,68]. Epidemio-
logical data and understanding of the mechanisms through which parasitic infections cause
morbidity in the human host are needed to develop similar models for other parasitic infection,
and update currently existing models. However, estimates made with such models are only use-
fully accurate if they are based on good information about the distribution of worms in host
populations. Since such data are not yet widely available and the development of mathematical
models is time-consuming and expensive, obtaining more precise estimates of the (averted)
burden of off-target infections remains a challenge.
We ignored that in 16 countries, ivermectin mass treatment was planned to be combined
with albendazole to target both onchocerciasis and LF from 2000 onwards [8]. However, 11
countries had not provided any LF treatment by 2010 (Angola, Burundi, Chad, Congo, DRC,
Equatorial Guinea, Liberia, Sudan, South Sudan), and two countries had only implemented
1–2 treatment rounds reaching<6% of the target population (Ethiopia and Central African
Republic) [69]. Only five countries (Cameroon, Malawi, Nigeria, Uganda, United Republic of
Tanzania) had more mature LF elimination programmes that supplied 3–11 treatment rounds
through 2010, reaching 25%–83% of the LF target population. We lack information on whether
LF treatments took place in areas with LF only or co-endemic areas, but countries might have
started in areas where mass treatment already took place for onchocerciasis. For these countries
(especially Nigeria where many people live in co-endemic areas) it is therefore perhaps not jus-
tified to fully attribute the estimated effects on off-target diseases to APOC alone. It would be
more useful to estimate the overall effect of repeated mass treatments on all target and off-tar-
get diseases; such estimates would be larger than the figures presented here, thanks to the addi-
tion of albendazole.
The so-called neglected tropical diseases (consisting of STH, filariases, EPSDs, and several
other infections) are the most common conditions affecting the poorest 500 million people liv-
ing in SSA [10,15]. The infections covered in our analysis have been estimated to be responsible
for a burden of 8.3 million DALYs lost in SSA in 2010 [14]. Compared to this, our estimate of
the health impact of ivermectin mass treatment on off-target diseases is modest (493 thousand
DALYs averted). In order to enhance the impact of mass treatment on LF and STH infections,
it would be interesting to consider adding albendazole or other STH-specific drugs to mass
treatments (targeting the appropriate age-groups). For instance, in a counterfactual scenario
where APOC would have added albendazole to their community-directed treatment strategy
from 2000 onwards, an additional 389 thousand DALYs would have been averted by 2010,
assuming that MDA would have had a higher impact on ascariasis, trichuriasis, hookworm,
and LF (i.e. βSTH = 0.9, instead of 0.5; βLF = 0.3, instead of 0.1). Guidelines for what anthel-
minthic drugs should be used in different areas have already been formulated [70]. Further, to
sustain the off-target health impact after onchocerciasis and LF have been eliminated from
APOC target areas, it should be considered to continue mass treatments against STH with
albendazole (possibly combined with ivermectin against trichuriasis [71]), either school-based
(mainly covering the burden of ascariasis and trichuriasis in children) or community-based
(covering the burden of all STH). This would also be in line with the London Declaration on
Neglected Tropical Diseases [72,73].
In conclusion, we roughly estimated that ivermectin mass treatment coordinated by APOC
has averted about 500 thousand DALYs related to off-target infections. This health impact con-
stitutes an additional 5.5% on top of the impact of APOC on the burden of onchocerciasis, and
indicates that the cost-effectiveness of APOC is even higher than previously estimated. To
amplify and sustain this additional health impact, control programs could consider adding
APOC 1995-2010: Impact on Off-Target Infectious Diseases
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albendazole to mass treatments, and continue this after elimination of onchocerciasis and lym-
phatic filariasis.
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